Quick answer: Therapeutic peptides—short chains of amino acids that act as biological signaling molecules—represent one of the most rapidly growing areas of functional and regenerative medicine. BPC-157 (Body Protection Compound) demonstrates remarkable tissue repair and anti-inflammatory effects across 30+ animal studies; sermorelin and CJC-1295/Ipamorelin stimulate growth hormone release with safety profiles superior to synthetic HGH; GLP-1 receptor agonists (semaglutide, tirzepatide) achieve 15-22% body weight reduction in Phase 3 trials (Wilding 2021, NEJM, n=1,961)—more than double the efficacy of any previous weight loss medication.
Peptide Therapeutics: The Science of Biological Signaling Molecules
Peptides—molecules composed of 2-50 amino acids joined by peptide bonds—occupy a unique pharmacological space between small molecules (conventional drugs) and large biologics (monoclonal antibodies, proteins). Unlike small molecules that typically inhibit a single enzyme or receptor, peptides interact with specific receptors or binding proteins with high affinity and specificity—often mimicking or modulating naturally occurring signaling pathways rather than imposing pharmacological effects foreign to normal physiology. Unlike large biologics, peptides can often be designed for subcutaneous or intranasal self-administration, have relatively short half-lives (reducing systemic accumulation concerns), and can be synthesized cost-effectively by solid-phase peptide synthesis.
The FDA has approved over 100 peptide drugs since the 1970s—including insulin (the first, 1921), vasopressin analogs, gonadotropin-releasing hormone agonists (leuprolide for prostate cancer), parathyroid hormone fragments (teriparatide for osteoporosis), and GLP-1 receptor agonists. The pharmaceutical pipeline contains over 400 peptide drugs in clinical development, making peptides one of the highest-growth therapeutic categories. The functional medicine peptide space includes both FDA-approved compounds (when used with appropriate clinical indication), compounded preparations from 503A compounding pharmacies (which can prepare non-commercially available peptides for specific patient needs under physician prescriptions), and a category of research peptides—peptides with preclinical but not yet human clinical trial data—which require careful evidence evaluation and regulatory awareness.
Growth Hormone Secretagogues: Sermorelin, CJC-1295, Ipamorelin
Growth hormone (GH) secretion declines approximately 14% per decade of adult life, reducing IGF-1 levels by 50% by age 60—contributing to reduced lean muscle mass, increased visceral adiposity, reduced bone mineral density, impaired cardiovascular function, diminished sleep quality, and impaired cognitive function that characterize somatopause. Synthetic recombinant human GH (rhGH, Humatrope, Genotropin) restores IGF-1 to youthful levels with documented improvements in body composition, bone density, and exercise capacity—but carries risks of supraphysiological IGF-1 levels promoting insulin resistance, potential malignancy risk at very high exposures (GH and IGF-1 are mitogenic signaling molecules), acromegalic features, and FDA approval only for documented GH deficiency (requiring stimulation testing with provocative agents like insulin-induced hypoglycemia or arginine/GHRH test, with peak GH below 5 ng/mL as cutoff).
Growth hormone secretagogues (GHS)—compounds that stimulate the pituitary to release endogenous GH rather than providing exogenous GH—offer a physiologically superior approach by preserving the pulsatile GH release pattern and hypothalamic-pituitary feedback mechanisms. Two categories: GHRH analogs (stimulating GHRH receptors on somatotrophs) and ghrelin receptor agonists/GHRPs (stimulating GH secretagogue receptors, GHS-R1a).
Sermorelin (GHRH 1-29, the active N-terminal fragment of endogenous GHRH) was FDA-approved for pediatric GH deficiency (withdrawn from market in 2008 due to commercial rather than safety reasons) and had extensive clinical use in adult GH optimization. Subcutaneous sermorelin 300-500 µg before bedtime (timed with the largest physiological GH pulse during early NREM sleep) stimulates pulsatile GH release with an effect that plateaus as the pituitary reaches maximum secretory capacity—providing a natural ceiling against supraphysiological IGF-1. Clinical studies demonstrated significant improvements in body composition (reduced fat mass, increased lean mass), bone mineral density, skin thickness, and sleep quality with 6-12 months of sermorelin use. Available from compounding pharmacies with physician prescription.
CJC-1295 (a modified GHRH analog with drug affinity complex [DAC] technology extending half-life to 8+ days via albumin binding) combined with Ipamorelin (a selective ghrelin receptor agonist with GH pulse-amplifying effects and no cortisol or prolactin side effects seen with earlier GHRPs) is the most widely prescribed GHS combination in functional medicine. The CJC-1295 DAC provides continuous GHRH receptor stimulation, while Ipamorelin amplifies GH pulse amplitude—together producing sustained IGF-1 elevation (30-50% increase over baseline with 2-3 months of 300 µg CJC-1295 DAC + 200-300 µg Ipamorelin 2-3× weekly injection) with favorable body composition effects. The combination avoids GHRP-2 and GHRP-6 cortisol and prolactin elevation. Available as compounded preparations; no FDA-approved version of the combination exists, requiring physician oversight through compounding pharmacy systems.
Tesamorelin (Egrifta)—an FDA-approved GHRH analog for HIV-associated lipodystrophy—provides the highest-quality clinical evidence for GHRH analogs in adults. Falutz 2010 NEJM (n=404, randomized controlled) demonstrated tesamorelin 2 mg/day significantly reduced visceral adipose tissue by 18% vs. placebo (p<0.001), with significant improvements in lipid profiles and no glycemic worsening. This represents the most rigorous evidence for a GHRH analog in adult body composition modification.
BPC-157: Body Protection Compound and Tissue Repair
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids) derived from a gastric juice protein sequence in humans. It has never undergone formal human clinical trials (despite a pilot human safety study—Sikiric 2017 data), but has accumulated an extraordinary body of animal research demonstrating tissue healing effects across multiple systems: tendon-to-bone healing acceleration, muscle injury repair, corneal wound healing, inflammatory bowel disease animal model remission, neurological protection, and cardiovascular anti-arrhythmic effects. The mechanism appears to involve nitric oxide (NO) pathway activation—BPC-157 increases eNOS expression and NO synthesis, modulates VEGF (vascular endothelial growth factor) to promote angiogenesis, activates the FAK-paxillin pathway in fibroblasts to promote cell migration, and modulates the dopamine and serotonin systems centrally.
The animal evidence for BPC-157 is exceptionally consistent across multiple research groups (primarily Sikiric’s group at the University of Zagreb Medical School, but replicated by independent groups) and across multiple models: Achilles tendon transection (complete healing in 2 weeks vs. 6 weeks for control groups, with histological normalization of collagen architecture—Sikiric 1998 J Orthop Res); inflammatory bowel disease (TNBS-induced colitis animal model with 100% remission at standard doses vs. standard treatments); neurological protection (reduces dopamine system dysfunction, 6-OHDA model—relevant to Parkinson’s); bone fracture healing (doubles healing speed in femur fracture models); and corneal wound healing (clinical translation potential for ocular surface disease). The extraordinary breadth of activity across tissue types without apparent toxicity at studied doses makes BPC-157 remarkable—and simultaneously raises questions about whether such a universally beneficial compound can be real without human trial validation.
Clinical use of BPC-157 in functional medicine: subcutaneous or intramuscular injection (200-500 µg once or twice daily) near the area of injury; oral capsules (500-1,000 µg/day—for gastrointestinal conditions, as oral BPC-157 has established activity in gut models but poor systemic absorption); or intranasally (for neurological applications). No human clinical pharmacokinetics have been published, making precise dosing recommendations speculative. The FDA has not approved BPC-157 for any indication, and as of 2023, the FDA sent letters to some compounding pharmacies questioning BPC-157’s eligibility for compounding under 503A—creating legal uncertainty around its commercial availability. Despite these limitations, BPC-157 has substantial practitioner use and enthusiastic patient reporting, justifying informed discussion while awaiting human clinical trial data.
GLP-1 Receptor Agonists: Semaglutide, Tirzepatide, and Weight Loss Medicine
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion, acting on the pancreatic beta-cell (stimulating glucose-dependent insulin secretion), the alpha-cell (suppressing glucagon), the hypothalamus (reducing appetite via arcuate nucleus POMC neuron activation and NPY/AgRP inhibition), the stomach (slowing gastric emptying and promoting satiety), and the cardiovascular system (reducing heart rate, blood pressure, and cardiovascular events independent of glucose lowering). Native GLP-1 has a half-life of 1-2 minutes due to rapid DPP-4 enzyme degradation; pharmaceutical GLP-1 receptor agonists (GLP-1 RAs) are engineered with extended half-lives of hours to weeks.
The STEP 1 trial (Wilding 2021, NEJM, n=1,961, semaglutide 2.4 mg/week subcutaneous vs. placebo) demonstrated 14.9% mean body weight reduction vs. 2.4% placebo at 68 weeks—with 86% of semaglutide recipients achieving at least 5% weight loss and 69% achieving at least 10% weight loss. This represented a paradigm shift: no previous pharmacological intervention had achieved outcomes approaching lifestyle intervention-equivalent weight loss. The SELECT trial (Lincoff 2023, NEJM, n=17,604 overweight/obese adults without diabetes) demonstrated semaglutide 2.4 mg/week reduced major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke) by 20% vs. placebo over 3.3 years—establishing GLP-1 RA as a cardiovascular protective medication independent of diabetes, transforming the indication beyond obesity to cardiovascular prevention.
Tirzepatide (Mounjaro/Zepbound)—a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist—achieves even greater weight reduction than semaglutide. The SURMOUNT-1 trial (Jastreboff 2022, NEJM, n=2,539) found tirzepatide 15 mg/week achieved 20.9% mean body weight reduction vs. 3.1% placebo—approaching weight loss achieved by bariatric surgery (typically 20-30% with Roux-en-Y gastric bypass). GIP receptor co-agonism appears to synergize with GLP-1 signaling in adipose tissue (reducing lipid accumulation) and the central nervous system (enhancing hypothalamic satiety signaling). The SURMOUNT-4 trial demonstrated that continued tirzepatide maintained weight loss while discontinuation resulted in significant weight regain—establishing that GLP-1/GIP receptor agonists treat but do not cure obesity, consistent with obesity’s chronic neurobiological nature.
GLP-1 receptor agonists in functional medicine context: these medications work most effectively as components of comprehensive lifestyle modification programs. Caloric restriction (even if spontaneously achieved via GLP-1-induced appetite reduction) must be accompanied by high-protein diet (1.2-1.6 g/kg/day) and resistance training to preserve lean muscle mass—GLP-1 RAs reduce fat AND muscle mass if protein intake and resistance training are inadequate, a clinical concern that has received increasing attention. Muscle mass preservation ensures that metabolic rate is maintained and functional outcomes (strength, metabolic health) accompany weight loss. Integration with functional medicine assessment (insulin resistance testing, inflammatory markers, microbiome assessment, sleep optimization) maximizes GLP-1 RA outcomes and addresses the metabolic disruptions that impair long-term weight maintenance.
Thymosin Alpha-1 and Immune Modulation
Thymosin alpha-1 (Tα1, Thymalfasin/Zadaxin)—a 28-amino acid peptide naturally produced by the thymus—is an FDA-cleared drug in multiple countries (China, Italy) for chronic hepatitis B, chronic hepatitis C, and as an immunostimulant in cancer patients receiving chemotherapy, though it carries investigational status in the US. Tα1 activates dendritic cell maturation and TLR9 signaling (enhancing innate immunity against viral and bacterial pathogens), promotes Th1 differentiation (IFN-γ, IL-2 production—the antiviral immune response), restores thymic output of naïve T-cells (relevant in aging-associated immunosenescence and post-chemotherapy lymphopenia), and modulates regulatory T-cell function. The antiviral evidence is strongest: Chen 2005 meta-analysis (n=480 HBV patients) found Tα1 superior to interferon-α for hepatitis B e-antigen seroconversion.
In functional medicine, Tα1 is used for: chronic viral infections (HBV, HCV, EBV reactivation, COVID-19 long-haul immune dysregulation—the Shi 2021 Journal of Infection trial found Tα1 significantly improved outcomes in severe COVID-19); post-COVID immune reconstitution (T-lymphopenia is common in PASC/long COVID—Tα1 promotes thymic T-cell production); chronic Lyme and co-infection immune support; malignancy-associated immunosuppression (improving vaccine responses and reducing infection risk during chemotherapy); and aging-associated immunosenescence. The typical dosing protocol is 1.6 mg subcutaneous injection twice weekly for 6 months—a schedule drawn from the hepatitis B trial data. Compounded Tα1 is available from specialty compounding pharmacies in the US under physician prescription.
Selank (TKPRPGP, a synthetic heptapeptide derived from tuftsin) and Semax (an ACTH 4-7 analog with Pro-Gly-Pro extension) are Russian-developed peptides with substantial published research (predominantly from Russian academic institutions) demonstrating anxiolytic, nootropic, and neuroprotective effects via BDNF upregulation, modulation of enkephalinase enzymes (reducing anxiety via endogenous opioid preservation), and GABA-A receptor modulation. Intranasally administered (the blood-brain barrier penetration route for these small peptides), Selank and Semax have been used clinically in Russia for anxiety, ADHD, depression, and cognitive optimization—but lack FDA approval or English-language RCT data meeting Western publication standards, requiring physician judgment about appropriate indication and oversight.
PT-141 (Bremelanotide): Sexual Function and Central Arousal
PT-141 (bremelanotide)—a synthetic melanocortin receptor agonist (primarily MC4R activation) derived from the tanning peptide Melanotan II—is FDA-approved as Vyleesi (intranasal, 1.75 mg as needed, premenopausal women with hypoactive sexual desire disorder/HSDD) and is used off-label in men for erectile dysfunction and low libido. Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally via vasodilation, PT-141 acts centrally—activating MC4R neurons in the paraventricular nucleus of the hypothalamus, initiating spontaneous sexual desire and arousal that precedes and drives peripheral arousal rather than requiring sexual stimulation first. The Palatin Technologies Phase 3 trial (Simon 2014, Obstetrics & Gynecology, n=276 HSDD women) found 1.75 mg intranasal PT-141 significantly improved satisfying sexual events (SSE) per month vs. placebo (2.5 vs. 1.7, p<0.001) with significant improvement in sexual desire.
In men, PT-141 subcutaneous injection (0.5-2 mg, 60-120 minutes before activity) activates central arousal pathways that may respond when PDE5 inhibitors have failed—particularly in men with low central libido drive rather than purely vascular ED. The mechanism complements PDE5 inhibitors rather than replacing them: PT-141 generates the desire and initiates the neurological arousal pathway; PDE5 inhibitors then maximize the vascular response to that arousal signal. For patients with diabetes-associated neuropathy (reduced genital sensitivity) or post-prostatectomy ED (reduced autonomic signaling), central arousal activation via PT-141 may recover sexual function partially lost due to peripheral neurological compromise. Side effects include transient nausea (most common, 40% of subjects), flushing, headache, and increased blood pressure (requires monitoring in hypertensive patients).
Frequently Asked Questions
Are peptide therapies safe, and are they FDA approved?
Peptide therapy safety varies dramatically by specific peptide and must be evaluated individually. FDA-approved peptides (sermorelin [withdrawn for commercial reasons, not safety], tesamorelin, semaglutide, tirzepatide, bremelanotide/PT-141, thymosin alpha-1 [approved outside US]) have extensive safety data from Phase 3 trials. Growth hormone secretagogues (CJC-1295/Ipamorelin, sermorelin) from compounding pharmacies have strong safety records in clinical use over 20+ years but lack the formal Phase 3 trial data of FDA-approved drugs. BPC-157 lacks any published human clinical pharmacokinetic or safety trials, though animal studies show remarkable safety even at supraphysiological doses and 30+ years of human use has not generated significant reported adverse event patterns. The key safety principle: work with a physician who monitors IGF-1, blood glucose, and relevant biomarkers during peptide use—peptides are not supplements and should not be used without medical oversight and individualized risk-benefit assessment.
How do GLP-1 medications like semaglutide and tirzepatide work, and who are they appropriate for?
GLP-1 receptor agonists work by mimicking the natural gut hormone GLP-1—reducing appetite via hypothalamic signaling, slowing gastric emptying for earlier satiety, and stimulating glucose-dependent insulin secretion. Semaglutide (Wegovy 2.4 mg/week) achieves 15% average weight loss and 20% cardiovascular event reduction (SELECT trial, n=17,604). Tirzepatide (Zepbound 15 mg/week) achieves 21% average weight loss—approaching bariatric surgery outcomes. Appropriate for: BMI above 30 (or 27+ with weight-related comorbidities), with or without type 2 diabetes, and particularly for those with elevated cardiovascular risk. Best results integrate these medications with high-protein diet (preventing muscle loss), resistance training, comprehensive metabolic assessment, and sleep optimization. Long-term use is typically required—discontinuation leads to significant weight regain, consistent with the chronic neurobiological nature of obesity.
What is BPC-157 used for, and what does the evidence show?
BPC-157 (Body Protection Compound-157) has accumulated 30+ animal studies demonstrating tissue healing across multiple systems: Achilles tendon transection healing doubled in speed (Sikiric 1998), inflammatory bowel disease remission in TNBS-induced colitis models, neurological protection in dopaminergic toxicity models, bone fracture healing acceleration, and corneal wound healing. The mechanism involves NO pathway activation, VEGF-mediated angiogenesis, and fibroblast activation via FAK-paxillin signaling. Human clinical trial data are absent—a critical limitation. Clinical practitioners report benefit for chronic tendinopathy, post-surgical healing, inflammatory bowel disease, and neurological conditions, typically using 200-500 µg subcutaneous or intramuscular injection, or 500-1,000 µg oral capsules for gastrointestinal applications. FDA regulatory status creates compounding availability uncertainty. Appropriate use requires physician oversight and informed patient consent regarding the absence of human trial data.
What are growth hormone secretagogues and how are they different from HGH?
Growth hormone secretagogues (GHS) stimulate the pituitary gland to release your own endogenous growth hormone—preserving the pulsatile secretion pattern and hypothalamic feedback mechanisms that make GH secretion physiologically safe. Synthetic recombinant HGH (rhGH) bypasses these regulatory mechanisms, producing constant supraphysiological GH levels that can cause insulin resistance, acromegalic features, and theoretical malignancy concerns at high doses—and is FDA-approved only for documented GH deficiency. Sermorelin (GHRH 1-29) and CJC-1295/Ipamorelin combinations stimulate GH release through natural pituitary mechanisms, achieving 30-50% IGF-1 increase with improved body composition, sleep quality, and recovery—without the safety concerns of exogenous HGH. The resulting IGF-1 levels remain within physiological ranges because pituitary secretory capacity provides a natural ceiling. Available through compounding pharmacies with physician prescription.
Therapeutic peptides represent the biological frontier of functional and regenerative medicine—harnessing naturally occurring signaling molecules to restore physiological processes with precision and specificity unmatched by conventional pharmaceuticals. From the proven efficacy of GLP-1 receptor agonists for obesity and cardiovascular prevention to the remarkable tissue-healing potential of BPC-157 and the growth hormone restoration of secretagogue protocols, peptide therapy offers a compelling toolkit for patients seeking restoration of optimal biological function. At The Private Practice, Dr. Biernacki evaluates peptide therapy candidates through comprehensive baseline assessment—including IGF-1, metabolic panel, inflammatory markers, and body composition analysis—and provides physician-supervised protocols with appropriate monitoring to ensure safety and efficacy. To discuss peptide therapy evaluation, call (810) 206-1402.